Literature DB >> 29482749

Fludeoxyglucose F 18 PET/CT Assessment of Ovarian Cancer.

Maria Cristina Marzola1, Sotirios Chondrogiannis2, Domenico Rubello2.   

Abstract

Ovarian cancer is one of the most common gynecologic cancers and one of the leading causes of cancer death in women. It is often asymptomatic in early stages, and thus most patients are diagnosed when it is of advanced stage. For these reasons, the role of biomarkers and tomographic imaging is crucial. Fludeoxyglucose F 18 PET/CT is a useful imaging modality in different clinical settings of the disease, overcoming some limits of conventional imaging and influencing prognosis and therapeutic approaches. PET/MR imaging is an emerging modality, and its potential role remains to be explored.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; FDG PET/CT; Ovarian cancer; Prognosis; Response to treatment; Staging

Mesh:

Substances:

Year:  2018        PMID: 29482749     DOI: 10.1016/j.cpet.2017.11.005

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  4 in total

1.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Authors:  Clemens Kratochwil; Paul Flechsig; Thomas Lindner; Labidi Abderrahim; Annette Altmann; Walter Mier; Sebastian Adeberg; Hendrik Rathke; Manuel Röhrich; Hauke Winter; Peter K Plinkert; Frederik Marme; Matthias Lang; Hans-Ulrich Kauczor; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

Review 2.  Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Authors:  Mayur Virarkar; Dhakshinamoorthy Ganeshan; Anjalie Tara Gulati; Sarah Palmquist; Revathy Iyer; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

Review 3.  Ovarian Cancer Targeted Theranostics.

Authors:  Sridhar Nimmagadda; Marie-France Penet
Journal:  Front Oncol       Date:  2020-01-21       Impact factor: 6.244

Review 4.  FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

Authors:  Tianshuo Yang; Long Ma; Haodong Hou; Feng Gao; Weijing Tao
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.